{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-26-000116","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2026-11-10T21:50:52+00:00","discovered_at":"2026-11-10T21:52:00.303005+00:00","generated_at":"2026-11-10T21:52:05.189965+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Gossamer Bio files first NDA for seralutinib in PAH; Q3 net loss $48.1M, cash $51.2M","bullets":["NDA for seralutinib in PAH submitted to FDA in September 2026, backed by Phase 3 PROSERA plus Phase 2 TORREY; FDA acceptance would unlock ~$125M.","Q3 2026 revenue from collaborators $38.4M vs $13.3M a year earlier, driven by $25.1M recognized on the July 2026 Chiesi collaboration termination.","Net loss $48.1M ($7.36/share) vs $48.2M ($16.92/share) in Q3 2025; R&D fell to $18.8M from $45.5M on lower seralutinib trial costs; G&A $9.6M.","Cash, equivalents and marketable securities $51.2M at Sept 30, 2026, down from $57.0M at June 30; structured placement delivered $25M upfront.","1-for-80 reverse stock split completed September 2026 to regain Nasdaq minimum bid price compliance; trading continues as GOSS."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-26-000116","json":"https://secwatch.observer/filing/0001728117-26-000116.json","markdown":"https://secwatch.observer/filing/0001728117-26-000116.md","text":"https://secwatch.observer/filing/0001728117-26-000116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811726000116/0001728117-26-000116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811726000116/goss-20261110.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-10T21:52:05.189965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}